Ludwig Institute for Cancer Research Limited

Smithkline Beecham Biologicals S.a.

Thierry Boon

Pierre Van Der Bruggen

Etienne De Plaen

Catia Traversari

Christophe Lurquin

Catherine Uyttenhove

Jacques Van Snick

Aline Van Pel

Benoit Van Den Eynde

Patrick Chomez

Janine M Bilsborough

Francis Brasseur

Erwin Schultz

Lan-Qing Huang

Christophe Panichelli

Silvia Silla

Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-β1) are provided, particularly recognizing human and mouse TGF-β1 and not recognizing or binding TGF-β2 or TGF-β3. Particular antibodies are provided which specifically recognize and neutralize TGF-β1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-β1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.

TGF-β1 specific antibodies and methods and uses thereof

Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-&#x3b2;1) are provided, particularly recognizing human and mouse TGF-&#x3b2;1 and not recognizing or binding TGF-&#x3b2;2 or TGF-&#x3b2;3. Particular antibodies are provided which specifically recognize and neutralize TGF-&#x3b2;1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-&#x3b2;1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-&#x3b2;1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.

TGF-&#xdf;1 specific antibodies and methods and uses thereof

TGF-&#x3b2;1 specific antibodies and methods and uses thereof

The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.

Isolated tumor rejection antigen precursor proteins MAGE-2 and MAGE-3

Polypeptides comprising an unbroken sequence of amino acids from SEQ ID NO: 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1.

Tumor rejection antigens

A peptide, previously identified as a binding partner of HLA-B44, has now been found to bind to HLA-B18 forming a T cell epitope. The therapeutic and diagnostic ramifications of this are the subject of this invention, as are various products obtained in the course of the development of the invention.

Isolated peptides which bind to HLA-B18 molecules and uses thereof

The invention involves the reception of particular nonapeptides by HLA molecules. The nonapeptides are derived from expression products of the MAGE gene family. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.

Method for treating cancer by administering MAGE-derived peptides

The present invention pertains to improved adjuvant compositions comprising a mixture of a saponin adjuvant such as QS21 with monophosphoryl lipid A or derivative thereof such as 3D-MPL and interleukin 12. These compositions are useful in a range of prophylactic and therapeutic applications, particularly in vaccines, including cancer vaccines.

Growing community of inventors

Brussels, Belgium

Thierry Boon